PCM
PGNX

Price Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Price Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-36,449
Closed -$218K – 249
2015
Q1 		$218K Buy
+36,449
New +$229K 0.14% 288

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Price Capital Management's PGNX Position: Q2 2015 in Review

Price Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2015, closing a stake of 36,449 shares — an estimated $218K sold.

Price Capital Management first reported a position in PGNX in Q1 2015 and held it in 1 quarter. The position peaked at $218K in Q1 2015. 121 funds tracked by Wall St. Rank hold PGNX as of Q2 2015.

  • Price Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 36,449 Progenics Pharmaceuticals Inc shares in Q2 2015, an estimated $218K.
  • Price Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Progenics Pharmaceuticals Inc position peaked at $218K in Q1 2015.
  • 121 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.